Advancements in cataract surgery have been remarkable over recent years, forging a forceful trajectory of progress since the first IOL was implanted; but which developments are really making an impact? Looking at recent advancements during Cataract Awareness Month, it’s clear there is a wealth of exciting new solutions to shout about.
Amongst some incredible advancements in monofocal, multifocal, toric and EDOF IOLs across the space, RxSight offers an innovative new solution in IOL technology. The Light Adjustable Lens uses Nobel-winning lens technology and office-based light treatment procedures to allow full customization of vision health, even after cataract surgery.
Whilst it might sound too good to be true, this advance is living up to the hype. Recent test subjects receiving RxSight’s Light Adjustable Lens over non-adjustable IOLs were twice as likely to achieve 20/20 distance vision at a 6-month marker than their counterparts.
Meanwhile, in the phacoemulsification space, means of cataract removal continue to reach new technological heights. The ZEISS patented QUATTRO Pump offers unrivalled chamber stability, independent of IOP and flow.
Working through a synchronised fluid exchange system controlling both infusion and aspiration volumes in real-time, the QUATTRO actively compensates for incision leakage volume. Safety and efficiency are of the highest quality, allowing work at the highest vacuum levels with minimised ultrasound requirements.
Femtosecond laser-assisted cataract surgery took a step into the future last June with the FDA clearance of the ALLY Adaptive Cataract Treatment System from LENSAR, a world-class imaging platform and next-generation dual-pulse femtosecond laser combined.
With easy integration with any OR or in-office surgery suite, ALLY can perform a completely sterile FLACS procedure, optimise workflow for surgeons, and reduce surgery time for patients. Unrivalled in efficiency, ALLY offers optimised adaptation, from precise incisions and automated capsulorhexis centration to tissue-specific femtosecond laser treatment.
Looking more broadly at adjacent developments in the Glaucoma treatment space, IOL-mounted drug delivery for glaucoma has continued to excel and mitigate more advanced cataract surgery needs.
Whilst still awaiting FDA approval at the time of writing, the world-first drug delivery platform from SpyGlass Pharma facilitates a 3-year delivery of bimatoprost for glaucoma treatment in a streamlined dual pad attachment to each haptic. Treatment is continuous over multiple years with minimal patient impact.
Enabling unprecedented IOL calculation, 2EyesVision from SimVis allows fully programmable, binocular multifocal corrective prescriptions without invasive testing, offering the best results yet for patients.
Intended for clinical use prior to intraocular lens implantation or contact lens fitting, 2EyesVision allows patients to experience the real world through multifocal corrections before the procedure. This technology optimises final vision health before surgery, a revolutionary step forward for modern cataract surgery.
Cataract surgery has experienced multiple advancements over recent years, transforming the practice into one of the most modern and efficient surgeries in ophthalmology. With significant improvements to patient experience, surgeon workflows, and prevention and management streamlining at every turn, the field looks set for continued breakthroughs.
When this creative use of technology is combined with optimised postoperative care, an improved standard of vision and quality of life looks set to become the standard, with less trauma caused by cataracts and respective treatments.
Want to find out more about Charlton Morris?
As frequency of eye disease rises with aging populations, these industry innovators are enabling earlier disease detection and creating more efficiency in the process. Click to find out more.